Articles

Company with Nanaimo lab gets federal approval for psychedelic drug research

Company with Nanaimo lab gets federal approval for psychedelic drug research

Numinus's recently amended Health Canada licence allows the company to produce and extract psilocybin from mushrooms. The Nanaimo News Bulletin speaks with Numinus CEO Payton Nyquvest about the…

Conversations That Matter: Payton Nyquvest and Dr. Evan Wood

Conversations That Matter: Payton Nyquvest and Dr. Evan Wood

In a special to the Vancouver Sun, Simon Fraser University's Stu McNish speaks with Numinus CEO Payton Nyquvest and Chief Medical Officer Dr. Evan Wood. Click here to read more.

Healthcare company Numinus looks to address mental health and addiction with psychedelic assisted therapy

Healthcare company Numinus looks to address mental health and addiction with psychedelic assisted therapy

Numinus leaders explore how research, development, testing, and treatment centres will be key to advancing and implementing psychedelic-assisted therapies. Click here to read more.

Healthcare company Numinus believes psychedelic assisted therapy can improve mental health outcomes

Healthcare company Numinus believes psychedelic assisted therapy can improve mental health outcomes

Numinus CEO Payton Nyquvest and Chief Medical Officer Dr. Evan Wood discuss the potential of psychedelic-assisted psychotherapy to transform existing treatment models of mental health and addition -…

The business of producing psychedelics for science

The business of producing psychedelics for science

The Daily Hive's Peter Smith speaks to Numinus CEO Payton Nyquvest about the business side of psychedelic-assisted therapy research and how Numinus's amended Health Canada licence puts them in a…

Medical Psilocybin and the Emerging “Functional” Mushrooms Market

Medical Psilocybin and the Emerging “Functional” Mushrooms Market

Investing News Network highlights the investment opportunity in the psychedelic-assisted therapy space and considers Numinus's unique position. Click here to read the full article.

Numinus licensed by Health Canada to extract and research psilocybin

Numinus licensed by Health Canada to extract and research psilocybin

Numinus CEO Payton Nyquvest and Chief Operating Officer Michael Tan spoke to Mugglehead about an amendment to the company's Health Canada licence which will allow them to produce and extract…

Numinus Licencing Amendment: We Speak to the Team

Numinus Licencing Amendment: We Speak to the Team

Numinus Chief Operating Officer Michael Tan explains what the company's recent Health Canada licence amendment, which will allow them to produce and extract psilocybin from mushrooms, means for…

Psychedelics Stocks to Watch

Psychedelics Stocks to Watch

Investing News Network highlights Numinus' unique value proposition in this article. Click here to read the full article.

We can no longer ignore the potential of psychedelic drugs to treat depression

We can no longer ignore the potential of psychedelic drugs to treat depression

Dr. Robin Carhart-Harris, Head of the Centre for Psychedelic Research at Imperial College London, writes of the Centre's work comparing psilocybin to conventional antidepressants and the potential of…

Growing body of research shows patients with addiction, PTSD, and depression can benefit from psychedelic substances

Growing body of research shows patients with addiction, PTSD, and depression can benefit from psychedelic substances

In a discussion with CannCentral, Numinus Wellness Chief Medical Officer Dr. Evan Wood cautions that psychedelic assisted psychotherapy is not a cure for everybody—but trials have shown statistically…

A Big Week For Psychedelics Co. Numinus Wellness

A Big Week For Psychedelics Co. Numinus Wellness

Benzinga highlights a busy week for Numinus, in which the company listed on the TSX Venture Exchange and appointed a new Chief Medical Officer, Dr. Evan Wood. Click here to read the full article.